MOUD Buprenorphine Subli denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for moud buprenorphine subli are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Sublingual Buprenorphine on Medical-Necessity Grounds

Sublingual buprenorphine is a core medication for opioid use disorder (MOUD). Despite its well-established clinical role, Aetna applies medical-necessity criteria that require documentation of the OUD diagnosis, the clinical severity of the disorder, the prescriber's qualifications, and — in some plan designs — evidence that the patient is engaged in or has been offered psychosocial support. Denials typically result from incomplete documentation in the authorization request, not from a genuine clinical disagreement about whether buprenorphine is appropriate for OUD.

## Why This Denial Is Appealable

Medical-necessity denials for MOUD are highly appellable on two independent grounds. First, if the clinical documentation exists in the chart and simply was not submitted, providing it resolves the denial. Second, the federal Mental Health Parity and Addiction Equity Act (MHPAEA) prohibits Aetna from applying medical-necessity criteria to opioid use disorder treatment that are more restrictive than those applied to analogous medical or surgical conditions. If Aetna's criteria are facially more burdensome for OUD than for comparable conditions, a parity challenge is warranted.

## Your Federal Appeal Rights

• Internal appeal (ERISA §503 / ACA §2719): You have a right to a full-and-fair internal review. File within the timeframe shown on the denial letter.
• MHPAEA parity argument: Raise parity expressly. Ask Aetna to identify the medical/surgical comparator and confirm equivalent application of medical-necessity standards.
• External review (ACA §2719): After internal exhaustion, an independent external reviewer issues a binding decision. The window is approximately 4 months from the final internal denial.
• Expedited review: Available when interruption of buprenorphine therapy would create an urgent health risk; response required within 72 hours.

## Documentation to Gather

1. OUD diagnosis confirmation — clinical notes, DSM-based diagnostic documentation, and relevant history establishing the diagnosis. 2. Clinical severity assessment — chart notes describing the patient's severity of disorder, functional impairment, and risk factors. 3. Prescriber credentials — confirmation that the prescribing clinician holds the appropriate DEA waiver or certification to prescribe MOUD (or documentation that no waiver is currently required under applicable law). 4. Treatment plan — a documented plan including buprenorphine dosing approach, monitoring plan, and any psychosocial support referral or engagement. 5. Prescriber medical-necessity letter — explicitly addressing each criterion in Aetna's policy and tying it to a specific chart fact.

## Criteria-Mapping Structure

Obtain Aetna's MOUD/buprenorphine clinical policy from their provider portal or member services. List every criterion. For each, cite the specific chart record that satisfies it: the note date, the clinician's finding, and the document type. Submit this as a structured table alongside the prescriber letter. A parity argument is most effective when your letter also requests, in writing, that Aetna disclose the comparable medical/surgical benefit and the criteria it applies to that benefit for side-by-side review.